Parkinson’s disease is a neurodegenerative disease characterized by gradual decrease of motor function. The progress is slow, and symptoms include bradykinesia, tremors, rigidity,
and postural instability. This is heavily associated with the degeneration of dopaminergic neurons in the substantia nigra.
The three currently known causes of this are the aggregation of α-synuclein proteins, high levels of ROS-induced inflammation in microglial cells, and mitochondrial dysfunction in neuronal cells.
Currently available therapies only provide symptomatic relief, by direct administration of dopamine derivatives or prevent breakdown of dopamine; there is no approved therapy for disease modification.
HSG4112 can serve as a fundamental disease-modifying treatment by reducing ROS and inflammation and by promoting mitophagy – recycling of damaged mitochondria – via PON2 protein. The restoration effects of dopaminergic neurons were confirmed in preclinical experiments.